Exploratory analysis of leucine-rich alpha-2-glycoprotein, C-reactive protein, and mucosal gene expression in budesonide-treated patients with ulcerative colitis

Introduction: Ulcerative colitis (UC) is a chronic inflammatory disease in which mucosal healing (MH) is an important therapeutic target. Because repeated endoscopic assessment is burdensome, noninvasive biomarkers such as leucine-rich alpha-2-glycoprotein (LRG) may be useful. This exploratory study examined serum LRG, C-reactive protein (CRP), and mucosal gene expression in patients with UC treated with budesonide 2-mg rectal foam. Methods: Outpatients with mild-to-moderate UC received budesonide 2-mg rectal foam twice daily for 6 weeks. Endoscopic findings, serum LRG and CRP levels, and mucosal gene expression were assessed at Week 0 and Week 6. Paired mucosal samples were available for 8 patients at non-inflamed sites and for 5 patients at inflamed sites. MH at Week 6 was defined as a Mayo endoscopic subscore ≤1, a rectal bleeding subscore of 0, and a stool frequency subscore ≤1. Results: Eight patients were included, and 4 (50.0%) achieved MH at Week 6. Serum LRG decreased in all 8 patients (P = 0.0078). The within-group P value was 0.1250 in both the MH and non-MH groups, and the change in LRG did not differ significantly between the groups (P = 0.2000). At the non-inflamed site, the panel-wide expression score decreased in 7 of 8 patients (P = 0.0547). Expression scores for 5 functional modules decreased in all 8 patients (P = 0.0078; q = 0.0313). At Week 0, 8 genes showed nominally higher expression at inflamed sites in patients without MH, although none remained significant after adjustment across the 249 analyzed genes. No adverse events were reported. Conclusion: Budesonide rectal foam treatment was followed by decreases in serum LRG and broad reductions in mucosal expression across the measured 249-gene panel. The study provided no evidence that the magnitude of the LRG change differed according to MH status. The observed gene-expression differences remain hypothesis-generating and require validation in independent cohorts.

Authors

Publication Details

Journal
Inflammatory Intestinal Diseases
Published
2026-11-21
DOI
https://doi.org/10.1159/iid/adeag016
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Exploratory analysis of leucine-rich alpha-2-glycoprotein, C-reactive protein, and mucosal gene expression in budesonide-treated patients with ulcerative colitis

Katsutoshi Inagaki, Katsuyoshi Matsuoka, Toshihide Ohmori, Toshiki Ichimori et al.
Inflammatory Intestinal Diseases
Inflammatory Bowel Disease
article

Exploratory analysis of leucine-rich alpha-2-glycoprotein, C-reactive protein, and mucosal gene expression in budesonide-treated patients with ulcerative colitis

Katsutoshi Inagaki, Katsuyoshi Matsuoka, Toshihide Ohmori, Toshiki Ichimori, Ken Takeuchi, Takayuki Matsumoto, Tetsuji Naka
article en

Abstract

Introduction: Ulcerative colitis (UC) is a chronic inflammatory disease in which mucosal healing (MH) is an important therapeutic target. Because repeated endoscopic assessment is burdensome, noninvasive biomarkers such as leucine-rich alpha-2-glycoprotein (LRG) may be useful. This exploratory study examined serum LRG, C-reactive protein (CRP), and mucosal gene expression in patients with UC treated with budesonide 2-mg rectal foam. Methods: Outpatients with mild-to-moderate UC received budesonide 2-mg rectal foam twice daily for 6 weeks. Endoscopic findings, serum LRG and CRP levels, and mucosal gene expression were assessed at Week 0 and Week 6. Paired mucosal samples were available for 8 patients at non-inflamed sites and for 5 patients at inflamed sites. MH at Week 6 was defined as a Mayo endoscopic subscore ≤1, a rectal bleeding subscore of 0, and a stool frequency subscore ≤1. Results: Eight patients were included, and 4 (50.0%) achieved MH at Week 6. Serum LRG decreased in all 8 patients (P = 0.0078). The within-group P value was 0.1250 in both the MH and non-MH groups, and the change in LRG did not differ significantly between the groups (P = 0.2000). At the non-inflamed site, the panel-wide expression score decreased in 7 of 8 patients (P = 0.0547). Expression scores for 5 functional modules decreased in all 8 patients (P = 0.0078; q = 0.0313). At Week 0, 8 genes showed nominally higher expression at inflamed sites in patients without MH, although none remained significant after adjustment across the 249 analyzed genes. No adverse events were reported. Conclusion: Budesonide rectal foam treatment was followed by decreases in serum LRG and broad reductions in mucosal expression across the measured 249-gene panel. The study provided no evidence that the magnitude of the LRG change differed according to MH status. The observed gene-expression differences remain hypothesis-generating and require validation in independent cohorts.

Inflammatory Intestinal Diseases
Inflammatory Bowel Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon